Pretax income is the income that a company earns before paying income taxes. MaxCyte's pretax income for the
three
months ended in Mar. 2024 was $-9.53 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-36.57 Mil.
MaxCyte's pretax margin was -83.99%.
During the past 12 years, MaxCyte's highest Pretax Margin was -15.57%. The lowest was -91.85%. And the median was -53.24%.
MaxCyte Pre-Tax Income Historical Data
The historical data trend for MaxCyte's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MaxCyte's Pre-Tax Income
For the Medical Devices subindustry, MaxCyte's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte's Pre-Tax Income Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where MaxCyte's Pre-Tax Income falls into.
MaxCyte Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
MaxCyte's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte (NAS:MXCT) Pre-Tax Income Explanation
MaxCyte's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 12 years, MaxCyte's highest Pretax Margin was -15.57%. The lowest was -91.85%. And the median was -53.24%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of MaxCyte's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MXCT has been successfully added to your 